Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
February 21, 2019 4:43 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More